Select publications

Bear HD et al. A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: Results of NSABP B-27. Presentation. San Antonio Breast Cancer Symposium, 2004;Abstract 26.

Bear HD et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21(22):4165-74. Abstract

Bonadonna G et al. Primary chemotherapy in operable breast cancer: Eight-year experience at the Milan Cancer Institute. J Clin Oncol 1998;16(1):93-100. Abstract

Burstein HJ et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing Stage II or III breast cancer: A pilot study. J Clin Oncol 2003;21(1):46-53. Abstract

Buzdar AU et al. Pathological complete response to chemotherapy is related to hormone receptor status. Breast Cancer Res Treat 2003;82(51);Abstract 302.

Buzdar AU et al. Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease. Proc ASCO 2004;Abstract 520.

Colleoni M et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: A study of preoperative treatment. Clin Cancer Res 2004;10(19):6622-8. Abstract

Ellis MJ et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB- 1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001;19(18):3808-16. Abstract

Fisher B et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16(8):2672-85. Abstract

Harris L et al. Preoperative trastuzumab and vinorelbine (HN) is a highly active, well-tolerated regimen for HER2 3+/FISH+ Stage II/III breast cancer. Proc ASCO 2003;Abstract 86.

Smith I et al. Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive (ER+) operable breast cancer in postmenopausal women: The IMPACT trial. Presentation. San Antonio Breast Cancer Symposium, 2003;Abstract 1.

Wolmark N et al. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;(30):96-102. Abstract